ASC Therapeutics logo

ASC Therapeutics

ASC Therapeutics develops biopharmaceuticals based on proprietary gene, CRISPR and allogeneic cell therapies

19 employees · est. 2008 · Milpitas, United States

VS
Corrixr Therapeutics logo

Corrixr Therapeutics

Destroying some of the deadliest squamous cell cancers at their source.

7 employees · est. 2022 · Newark, United States

ASC Therapeutics is the older company (2008 vs 2022); ASC Therapeutics is the larger of the two.

Side-by-Side Comparison

ASC Therapeutics Corrixr Therapeutics
Founded
2008 older 2022
Headquarters
Milpitas, United States Newark, United States
Employees
19 larger 7
Industry
Biopharma, Biotechnology, Health Care Biotechnology, Health Care, Health and Wellness
Funding Stage
Not tracked yet Seed
Total Funding
Not tracked yet $6.53M
Funding Rounds
Not tracked yet 2
Services
Not tracked yet Development of targeted genetic therapies, Disabling NRF2 in squamous cell cancers, Localized genetic delivery to tumors
Target Customers
Not tracked yet Patients with lung squamous cell carcinoma, Patients with head & neck squamous cell carcinoma, Patients with esophageal squamous cell carcinoma, Oncologists seeking innovative treatments, Healthcare providers specializing in oncology
Taxonomy
Gene Therapy, Cell Therapy, CRISPR, Blood Disorders, Rare Diseases, Genome Editing, Biopharmaceuticals, Stem Cells, Clinical Research, Biotech Venture, Drug Development Oncology, Biotherapeutics, Gene Editing, CRISPR/Cas, Pre-clinical Stage, Gene Therapy, Solid Tumors, Clinical Frontier, Therapeutic Platform, Drug-resistant, Innovation, Precision Medicine, Clinical Trials, Oncology Research
Website
asctherapeutics.com corrixr.com
ASC Therapeutics logo

About ASC Therapeutics

ASC Therapeutics is a biopharmaceutical company that specializes in the development of gene, CRISPR, and allogeneic cell therapies for rare diseases. The company's focus lies in the development of curative therapies for monogenic blood disorders with high genetic penetrance and conditions requiring...

Corrixr Therapeutics logo

About Corrixr Therapeutics

CorriXR Therapeutics, founded in 2022, is an emerging force in the biotechnology and health care sectors. Based in the United States, the company is carving out a niche in the development of oncology-focused biotherapeutics through its revolutionary in vivo gene editing platform. The company is uti...

We will tell you when either one moves

BounceWatch watches ASC Therapeutics and Corrixr Therapeutics for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at ASC Therapeutics and Corrixr Therapeutics — by email.

Frequently Asked Questions

ASC Therapeutics — ASC Therapeutics develops biopharmaceuticals based on proprietary gene, CRISPR and allogeneic cell therapies. Corrixr Therapeutics — Destroying some of the deadliest squamous cell cancers at their source. . Both companies operate in related markets but may differ in funding stage, team size, and product focus.
ASC Therapeutics has raised undisclosed funding while Corrixr Therapeutics has raised $6.53M.
ASC Therapeutics and Corrixr Therapeutics operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare ASC Therapeutics with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at ASC Therapeutics on 16 Nov 2024, and Corrixr Therapeutics on 12 Sep 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy